A pharmaceutical composition comprising a compound of formula I: or a salt, hydrate, or solvate thereof; wherein: R 1 is arylalkyl or heteroarylalkyl, each optionally substituted with 1-4 independent Z 1; R 3 is hydrogen, hydroxyl, alkoxy, or alkylamino; R 6 is optionally substituted aryl, substituted heteroaryl, or partially unsaturated heterocyclyl, wherein R 6 is optionally substituted by 1-3 groups, independently selected from alkyl, cycloalkyl, heterocyclyl, alkoxy, hydroxyalkyl, -C NR 7 R 8, and Z 1; each of which may be further optionally substituted; R 7 and R 8 are each independently selected from H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, or R 7 and R 8 together with nitrogen form an optionally substituted heterocyclyl or optionally substituted heteroaryl; each Z 1 is halogen, CN, NO 2, OR 15, SR 15, S 2 OR 15, NR 15 R 16, C 1 -C 2 perfluoroalkyl, C 1 -C 2 perfluoroalkoxy, 1,2-methylenedioxy, C OR 15, C NR 15 R 16, OC NR 15 R 16, NR 15 C NR 15 R 16, C(NR 16)NR 15 R 16, NR 15 C(NR 16)NR 15 R 16, S 2 NR 15 R 16, R 17, C R 17, NR 15 C R 17, S R 17; S 2 R 17, R 16, oxo, C R 16, C (CH 2)nOH, (CH 2)nOR 15, (CH 2) n C NR 15 R 16, NR 15 S 2 R 17, where n is independently 0-6 inclusive; each R 15 is independently hydrogen, C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl; each R 16 is independently hydrogen, alkenyl, alkynyl, C 3 -C 6 cycloalkyl, aryl, heterocyclyl, heteroaryl, C 1 -C 4 alkyl or C 1 -C 4 alkyl substituted with C 3 -C 6 cycloalkyl, aryl, heterocyclyl or heteroaryl; and each R 17 is independently C 3 -C 6 cycloalkyl, aryl, heterocyclyl, heteroaryl, C 1 -C 4 alkyl or C 1 -C 4 alkyl substituted with C 3 -C 6 cycloalkyl, aryl, heterocyclyl or heteroaryl. R 1 is arylalkyl or heteroarylalkyl, each optionally substituted with 1-4 independent Z 1; R 3 is hydrogen, hydroxyl, alkoxy, or alkylamino; R 6 is optionally substituted aryl, substituted heteroaryl, or partially unsaturated heterocyclyl, wherein R 6 is optionally substituted by 1-3 groups, independently selected from alkyl, cycloalkyl, heterocyclyl, alkoxy, hydroxyalkyl, -C NR 7 R 8, and Z 1; each of which may be further optionally substituted; R 7 and R 8 are each independently selected from H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, or R 7 and R 8 together with nitrogen form an optionally substituted heterocyclyl or optionally substituted heteroaryl; each Z 1 is halogen, CN, NO 2, OR 15, SR 15, S 2 OR 15, NR 15 R 16, C 1 -C 2 perfluoroalkyl, C 1 -C 2 perfluoroalkoxy, 1,2-methylenedioxy, C OR 15, C NR 15 R 16, OC NR 15 R 16, NR 15 C NR 15 R 16, C(NR 16)NR 15 R 16, NR 15 C(NR 16)NR 15 R 16, S 2 NR 15 R 16, R 17, C R 17, NR 15 C R 17, S R 17; S 2 R 17, R 16, oxo, C R 16, C (CH 2)nOH, (CH 2)nOR 15, (CH 2) n C NR 15 R 16, NR 15 S 2 R 17, where n is independently 0-6 inclusive; each R 15 is independently hydrogen, C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl; each R 16 is independently hydrogen, alkenyl, alkynyl, C 3 -C 6 cycloalkyl, aryl, heterocyclyl, heteroaryl, C 1 -C 4 alkyl or C 1 -C 4 alkyl substituted with C 3 -C 6 cycloalkyl, aryl, heterocyclyl or heteroaryl; and each R 17 is independently C 3 -C 6 cycloalkyl, aryl, heterocyclyl, heteroaryl, C 1 -C 4 alkyl or C 1 -C 4 alkyl substituted with C 3 -C 6 cycloalkyl, aryl, heterocyclyl or heteroaryl.